Rabeprazole: an update of its use in acid-related disorders (Q34481309)

2 August 2017

1 reference

title

Rabeprazole: an update of its use in acid-related disorders (English)

1 reference

2 August 2017

C I Carswell

1

1 reference

PubMed ID

11772142

2 August 2017

K L Goa

series ordinal

2

1 reference

2 August 2017

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

61

1 reference

2 August 2017

15

1 reference

2 August 2017

2327-2356

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200161150-00016

2 August 2017

0 references

cites work

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection

1 reference

12 December 2020

Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso

1 reference

12 December 2020

Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).

1 reference

12 December 2020

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

1 reference

12 December 2020

Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication.

1 reference

12 December 2020

Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection

1 reference

12 December 2020

Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

1 reference

12 December 2020

Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group

1 reference

12 December 2020

Helicobacter pylori eradication in patients with non-ulcer dyspepsia

1 reference

12 December 2020

Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease

1 reference

12 December 2020

Formulary management of proton pump inhibitors

1 reference

12 December 2020

A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori

1 reference

12 December 2020

The benefit/risk profile of rabeprazole, a new proton-pump inhibitor

1 reference

12 December 2020

An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).

1 reference

12 December 2020

Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders

1 reference

12 December 2020

Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1 reference

12 December 2020

Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole

1 reference

12 December 2020

Rabeprazole: a review of its use in acid-related gastrointestinal disorders

1 reference

12 December 2020

In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori

1 reference

12 December 2020

Rabeprazole is superior to omeprazole for the inhibition of peptone meal‐stimulated gastric acid secretion in Helicobacter pylori‐negative subjects

1 reference

12 December 2020

Helicobacter pylori infection and eradication in paediatric patients

1 reference

12 December 2020

Review article: rabeprazole's tolerability profile in clinical trials

1 reference

12 December 2020

Management of gastro-oesophageal reflux disease in general practice

1 reference

12 December 2020

Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group

1 reference

12 December 2020

Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group

1 reference

12 December 2020

5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication

1 reference

12 December 2020

The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers

1 reference

12 December 2020

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

1 reference

12 December 2020

Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis.

1 reference

12 December 2020

Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy

1 reference

12 December 2020

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

1 reference

12 December 2020

Finding the optimum treatment for Helicobacter pylori

1 reference

12 December 2020

Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome

1 reference

12 December 2020

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

1 reference

12 December 2020

Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure.

1 reference

12 December 2020

Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group

1 reference

12 December 2020

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status

1 reference

12 December 2020

Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.

1 reference

12 December 2020

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.

1 reference

12 December 2020

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

1 reference

12 December 2020

Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis

1 reference

12 December 2020

Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection

1 reference

12 December 2020

Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole

1 reference

12 December 2020

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group

1 reference

12 December 2020

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.

1 reference

12 December 2020

Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide

1 reference

12 December 2020

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group

1 reference

12 December 2020

Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers.

1 reference

12 December 2020

Acute fulminant hepatitis after treatment with rabeprazole and terbinafine

1 reference

12 December 2020

Review article: the pharmacokinetics of rabeprazole in health and disease

1 reference

12 December 2020

Novel therapeutic approaches to gastric and duodenal ulcers: an update

1 reference

12 December 2020

A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects

1 reference

12 December 2020

Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial

1 reference

12 December 2020

Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications

1 reference

12 December 2020

How do we offer clinical relief to patients with gastro-oesophageal reflux disease?

1 reference

12 December 2020

Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.

1 reference

12 December 2020

Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.

1 reference

12 December 2020

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.

1 reference

12 December 2020

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

1 reference

12 December 2020

Strategies for medical management of reflux disease

1 reference

12 December 2020

10.2165/00003495-200161150-00016

Identifiers

DOI

1 reference

PubMed ID

11772142

Dimensions Publication ID

2 August 2017

0 references

1 reference

PubMed ID

11772142